Clinical significance of the ratio between the alpha 2 plasmin inhibitor-plasmin complex and the thrombin-antithrombin complex in advanced non-small cell lung cancer

Medical Oncology

Volumn 28, Issue 1, 2011, Pages 351-356

  Masago, Katsuhiro ^a   Fujita, Shiro ^b   Mio, Tadashi ^a   Togashi, Yosuke ^a   Kim, Young Hak ^a   Hatachi, Yukimasa ^a   Fukuhara, Akiko ^a   Irisa, Kaoru ^a   Sakamori, Yuichi ^a   Mishima, Michiaki ^a  

^a KYOTO UNIVERSITY   (Japan)

^b INSTITUTE OF BIOMEDICAL RESEARCH AND INNOVATION   (Japan)

Author keywords

D dimmer; Non small cell lung cancer; Plasmin a2 plasmin inhibitor complex (PIC); Prognostic factor; Thrombin antithrombin complex (TAT)

Indexed keywords

ALPHA 2 ANTIPLASMIN; D DIMER; THROMBIN ANTITHROMBIN COMPLEX;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER SURVIVAL; CLINICAL EVALUATION; CONTROLLED STUDY; DISEASE MARKER; FEMALE; HEMOSTASIS; HUMAN; LUNG NON SMALL CELL CANCER; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; SURVIVAL TIME;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ALPHA-2-ANTIPLASMIN; ANTITHROMBIN III; BLOOD COAGULATION; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; FEMALE; FIBRINOLYSIN; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PEPTIDE HYDROLASES; PROGNOSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 79952245642     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12032-010-9454-y     Document Type: Article

References (25)

1. D Antoniou G Pavlakou GP Stathopoulos, et al. 2006 Predictive value of D-dimer plasma levels in response and progressive disease in patients with lung cancer Lung Cancer 53 205 210 16769149 10.1016/j.lungcan.2006.03.015 (Pubitemid 43994226)
2. G Buccheri P Torchio D Ferrigno 2003 Plasma levels of D-dimer in lung carcinoma: clinical and prognostic significance Cancer 97 3044 3052 12784340 10.1002/cncr.11432 1:CAS:528:DC%2BD3sXlt1Shurg%3D (Pubitemid 36676259)
3. EC Gabazza O Taguchi T Yamakami, et al. 1993 Evaluating prethrombotic state in lung cancer using molecular markers Chest 103 196 200 7678080 10.1378/chest.103.1.196 1:STN:280:DyaK3s7hsVSgsQ%3D%3D (Pubitemid 23027258)
4. E Unsal F Atalay S Atikcan, et al. 2004 Prognostic significance of hemostatic parameters in patients with lung cancer Respir Med 98 93 98 14971870 10.1016/j.rmed.2003.07.001 (Pubitemid 38181125)
5. SG Gordon 1992 Cancer cell procoagulants and their role in malignant disease Semin Thromb Hemost 18 424 433 1470929 10.1055/s-2007-1002580 1:STN:280:DyaK3s7htVeksg%3D%3D (Pubitemid 23190621)
6. RL Bick 1992 Coagulation abnormalities in malignancy: a review Semin Thromb Hemost 18 353 372 1470924 10.1055/s-2007-1002575 1:STN:280: DyaK3s7htVeltw%3D%3D (Pubitemid 23190616)
7. O Taguchi EC Gabazza M Yoshida, et al. 1996 High plasma level of plasmin-alpha 2-plasmin inhibitor complex is predictor of poor prognosis in patients with lung cancer Clin Chim Acta 244 69 81 8919202 10.1016/0009-8981(95) 06196-7 1:CAS:528:DyaK28XkslKrtg%3D%3D (Pubitemid 26050201)
8. R Seitz HH Heidtmann M Wolf, et al. 1997 Prognostic impact of an activation of coagulation in lung cancer Ann Oncol 8 781 784 9332686 10.1023/A:1008240918434 1:STN:280:DyaK2svntlyntg%3D%3D (Pubitemid 27397902)
9. J Watine 1998 Prognostic impact of an activation of coagulation in lung cancer Ann Oncol 9 1255 1256 9862059 10.1023/A:1008481331944 1:STN:280:DyaK1M%2FnvFSmsA%3D%3D (Pubitemid 28552818)
10. H Pelzer A Schwarz N Heimburger 1988 Determination of human thrombin-antithrombin III complex in plasma with an enzyme-linked immunosorbent assay Thromb Haemost 59 101 106 3363526 1:STN:280:DyaL1c3gsFamtQ%3D%3D (Pubitemid 18053658)
11. J Mimuro Y Koike Y Sumi, et al. 1987 Monoclonal antibodies to discrete regions in alpha 2-plasmin inhibitor Blood 69 446 453 2948579 1:CAS:528:DyaL2sXitV2qsbg%3D (Pubitemid 17022012)
12. KE Goad HR Gralnick 1996 Coagulation disorders in cancer Hematol Oncol Clin North Am 10 457 484 8707764 10.1016/S0889-8588(05)70347-6 1:STN:280:DyaK283psFKltw%3D%3D (Pubitemid 26097347)
13. G Altiay A Ciftci M Demir, et al. 2007 High plasma D-dimer level is associated with decreased survival in patients with lung cancer Clin Oncol (R Coll Radiol) 19 494 498 1:STN:280:DC%2BD2svls1GisA%3D%3D (Pubitemid 47181178)
14. G Buccheri D Ferrigno C Ginardi, et al. 1997 Haemostatic abnormalities in lung cancer: prognostic implications Eur J Cancer 33 50 55 9071899 10.1016/S0959-8049(96)00310-3 1:STN:280:DyaK2s3isFGmtQ%3D%3D (Pubitemid 27099567)
15. F Langer B Spath K Haubold, et al. 2008 Tissue factor procoagulant activity of plasma microparticles in patients with cancer-associated disseminated intravascular coagulation Ann Hematol 87 451 457 18292996 10.1007/s00277-008-0446-3 1:CAS:528:DC%2BD1cXkvFSjtr0%3D
16. SJ Pavey GA Hawson NA Marsh 2001 Impact of the fibrinolytic enzyme system on prognosis and survival associated with non-small cell lung carcinoma Blood Coagul Fibrinolysis 12 51 58 11229827 10.1097/00001721-200101000-00008 1:CAS:528:DC%2BD3MXhtVaqsLc%3D (Pubitemid 32150252)
17. O Taguchi EC Gabazza H Yasui, et al. 1997 Prognostic significance of plasma D-dimer levels in patients with lung cancer Thorax 52 563 565 9227726 10.1136/thx.52.6.563 1:STN:280:DyaK2szntFGjsw%3D%3D (Pubitemid 27298511)
18. HC Kwaan HN Keer 1990 Fibrinolysis and cancer Semin Thromb Hemost 16 230 235 2146746 10.1055/s-2007-1002674 1:STN:280:DyaK3M%2FkvVSiuw%3D%3D (Pubitemid 20289930)
19. MC Alessi N Chomiki R Berthier, et al. 1994 Detection of plasminogen activator inhibitor-1 (PAI-1) mRNA in human megakaryocytes by in situ hybridization Thromb Haemost 72 931 936 7740466 1:CAS:528:DyaK2MXivVygsro%3D
20. S Madoiwa N Komatsu J Mimuro, et al. 1999 Developmental expression of plasminogen activator inhibitor-1 associated with thrombopoietin-dependent megakaryocytic differentiation Blood 94 475 482 10397715 1:CAS:528: DyaK1MXksVemtL8%3D (Pubitemid 29323862)
21. HF Dvorak 1986 Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing N Engl J Med 315 1650 1659 3537791 10.1056/NEJM198612253152606 1:STN:280:DyaL2s%2FmsV2mtw%3D%3D (Pubitemid 17052899)
22. MN Levine AY Lee AK Kakkar 2003 From Trousseau to targeted therapy: new insights and innovations in thrombosis and cancer J Thromb Haemost 1 1456 1463 12871280 10.1046/j.1538-7836.2003.00275.x 1:CAS:528:DC%2BD2cXktFOjsb4%3D
23. SM Smorenburg CJ Van Noorden 2001 The complex effects of heparins on cancer progression and metastasis in experimental studies Pharmacol Rev 53 93 105 11171940 1:CAS:528:DC%2BD3MXhsFWqtb4%3D (Pubitemid 32173109)
24. S Schulman P Lindmarker 2000 Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism. Duration of anticoagulation trial N Engl J Med 342 1953 1958 10874063 10.1056/NEJM200006293422604 1:STN:280:DC%2BD3czit1arsQ%3D%3D (Pubitemid 30419090)
25. EA Akl P Muti HJ Schunemann 2008 Anticoagulation in patients with cancer: an overview of reviews Pol Arch Med Wewn 118 183 193 18575417 (Pubitemid 351613058)